Nothing
tests/testthat/_snaps/l_vs_slide.md
In autoslider.core: Slide Automation for Tables, Listings and Figures
Test listing creation of l_vs_slide (Vital Signs Listing)
Code
l_vs_slide(adsl = adsl, advs = advs, trt_var = "TRT01A")
Output
Listing of Vital Signs: Safety-Evaluable Patients
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
A: Drug X BRA-1/93 34/F/ASIAN WEEK 1 DAY 8 402 47.51 35.50/L 94.27 98.82/L 72.44 14.97
WEEK 2 DAY 15 460 67.64 37.96/H 109.98 104.21/L 104.70/H 14.90
WEEK 3 DAY 22 464 53.06 36.33 90.17 139.66 111.13/H 22.86/H
WEEK 4 DAY 29 496 61.68 33.52/L 112.76 128.82 72.89 20.77/H
WEEK 5 DAY 36 538 53.98 35.71/L 80.20 137.16 96.63 18.10
B: Placebo BRA-1/236 32/M/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 486 37.04/L 36.11 120.31/H 146.04 65.75 22.69/H
WEEK 2 DAY 15 678 80.66 35.64/L 106.20 146.80 82.04 16.89
WEEK 3 DAY 22 762 86.71 36.16 104.63 76.01/L 70.13 19.70
WEEK 4 DAY 29 773 48.43 35.38/L 111.13 134.79 80.78 17.98
WEEK 5 DAY 36 901 24.05/L 35.90/L 108.01 137.95 68.35 8.48/L
BRA-1/65 25/F/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 546 60.68 34.67/L 113.72 132.45 76.37 16.70
WEEK 2 DAY 15 604 55.85 38.63/H 127.03/H 133.52 93.95 15.08
WEEK 3 DAY 22 723 47.66 37.02 116.06 91.36/L 62.00 3.89/L
WEEK 4 DAY 29 791 116.89/H 37.90/H 113.53 170.65 96.86 6.73/L
WEEK 5 DAY 36 800 56.73 36.81 141.54/H 165.15 75.85 23.02/H
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
l_vs_slide works without a treatment variable
Code
l_vs_slide(adsl = adsl, advs = advs, trt_var = NULL)
Output
Listing of Vital Signs: Safety-Evaluable Patients
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
BRA-1/236 32/M/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 486 37.04/L 36.11 120.31/H 146.04 65.75 22.69/H
WEEK 2 DAY 15 678 80.66 35.64/L 106.20 146.80 82.04 16.89
WEEK 3 DAY 22 762 86.71 36.16 104.63 76.01/L 70.13 19.70
WEEK 4 DAY 29 773 48.43 35.38/L 111.13 134.79 80.78 17.98
WEEK 5 DAY 36 901 24.05/L 35.90/L 108.01 137.95 68.35 8.48/L
BRA-1/65 25/F/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 546 60.68 34.67/L 113.72 132.45 76.37 16.70
WEEK 2 DAY 15 604 55.85 38.63/H 127.03/H 133.52 93.95 15.08
WEEK 3 DAY 22 723 47.66 37.02 116.06 91.36/L 62.00 3.89/L
WEEK 4 DAY 29 791 116.89/H 37.90/H 113.53 170.65 96.86 6.73/L
WEEK 5 DAY 36 800 56.73 36.81 141.54/H 165.15 75.85 23.02/H
BRA-1/93 34/F/ASIAN WEEK 1 DAY 8 402 47.51 35.50/L 94.27 98.82/L 72.44 14.97
WEEK 2 DAY 15 460 67.64 37.96/H 109.98 104.21/L 104.70/H 14.90
WEEK 3 DAY 22 464 53.06 36.33 90.17 139.66 111.13/H 22.86/H
WEEK 4 DAY 29 496 61.68 33.52/L 112.76 128.82 72.89 20.77/H
WEEK 5 DAY 36 538 53.98 35.71/L 80.20 137.16 96.63 18.10
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
l_vs_slide is generated correctly from the spec.yml
Code
outputs
Output
$l_vs_slide_PP128
Listing of Vital Signs: Safety-Evaluable Patients
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
A: Drug X CHN-3/128 32/M/ASIAN WEEK 1 DAY 8 408 85.96 37.06 77.15/L 160.71 77.01 12.71
WEEK 2 DAY 15 662 104.28/H 36.99 101.50 136.92 51.40/L 13.86
WEEK 3 DAY 22 776 74.19 37.90/H 121.95/H 135.94 74.71 17.84
WEEK 4 DAY 29 923 80.48 36.51 81.22 115.51/L 83.30 15.45
WEEK 5 DAY 36 1015 61.36 38.22/H 76.83/L 164.55 90.36 10.36/L
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
$l_vs_slide_PP262
Listing of Vital Signs: Safety-Evaluable Patients
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
C: Combination CHN-15/262 35/M/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 428 96.54 38.18/H 123.51/H 132.81 79.73 15.30
WEEK 2 DAY 15 471 65.91 34.89/L 109.00 130.82 65.32 11.56/L
WEEK 3 DAY 22 483 93.99 35.14/L 82.01 161.65 61.17 22.53/H
WEEK 4 DAY 29 661 68.79 37.00 127.87/H 155.19 56.88/L 19.64
WEEK 5 DAY 36 1025 73.16 38.41/H 95.87 113.91/L 84.02 18.41
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
$l_vs_slide_PP378
Listing of Vital Signs: Safety-Evaluable Patients
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
C: Combination RUS-3/378 30/F/ASIAN WEEK 1 DAY 8 428 95.11 37.57/H 90.52 113.37/L 83.55 17.54
WEEK 2 DAY 15 501 71.73 38.00/H 96.79 145.53 111.55/H 21.99/H
WEEK 3 DAY 22 701 59.10 36.67 77.14/L 149.26 68.95 17.32
WEEK 4 DAY 29 745 57.88 37.67/H 132.52/H 142.93 86.05 6.36/L
WEEK 5 DAY 36 885 43.44 36.40 97.38 183.98/H 82.18 19.05
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
$l_vs_slide_PP220
Listing of Vital Signs: Safety-Evaluable Patients
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
B: Placebo CHN-11/220 26/F/ASIAN WEEK 1 DAY 8 284 93.75 33.03/L 132.89/H 165.75 78.09 18.00
WEEK 2 DAY 15 403 64.44 35.93/L 116.93 101.12/L 92.92 18.57
WEEK 3 DAY 22 634 86.18 36.07/L 115.34 134.15 66.07 16.20
WEEK 4 DAY 29 685 70.70 37.16 108.18 145.76 92.05 13.04
WEEK 5 DAY 36 1027 67.53 36.85 137.64/H 187.10/H 74.17 18.61
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
Try the autoslider.core package in your browser
Any scripts or data that you put into this service are public.
autoslider.core documentation built on Sept. 29, 2026, 5:08 p.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Test listing creation of l_vs_slide (Vital Signs Listing)
Code
l_vs_slide(adsl = adsl, advs = advs, trt_var = "TRT01A")
Output
Listing of Vital Signs: Safety-Evaluable Patients
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
A: Drug X BRA-1/93 34/F/ASIAN WEEK 1 DAY 8 402 47.51 35.50/L 94.27 98.82/L 72.44 14.97
WEEK 2 DAY 15 460 67.64 37.96/H 109.98 104.21/L 104.70/H 14.90
WEEK 3 DAY 22 464 53.06 36.33 90.17 139.66 111.13/H 22.86/H
WEEK 4 DAY 29 496 61.68 33.52/L 112.76 128.82 72.89 20.77/H
WEEK 5 DAY 36 538 53.98 35.71/L 80.20 137.16 96.63 18.10
B: Placebo BRA-1/236 32/M/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 486 37.04/L 36.11 120.31/H 146.04 65.75 22.69/H
WEEK 2 DAY 15 678 80.66 35.64/L 106.20 146.80 82.04 16.89
WEEK 3 DAY 22 762 86.71 36.16 104.63 76.01/L 70.13 19.70
WEEK 4 DAY 29 773 48.43 35.38/L 111.13 134.79 80.78 17.98
WEEK 5 DAY 36 901 24.05/L 35.90/L 108.01 137.95 68.35 8.48/L
BRA-1/65 25/F/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 546 60.68 34.67/L 113.72 132.45 76.37 16.70
WEEK 2 DAY 15 604 55.85 38.63/H 127.03/H 133.52 93.95 15.08
WEEK 3 DAY 22 723 47.66 37.02 116.06 91.36/L 62.00 3.89/L
WEEK 4 DAY 29 791 116.89/H 37.90/H 113.53 170.65 96.86 6.73/L
WEEK 5 DAY 36 800 56.73 36.81 141.54/H 165.15 75.85 23.02/H
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
l_vs_slide works without a treatment variable
Code
l_vs_slide(adsl = adsl, advs = advs, trt_var = NULL)
Output
Listing of Vital Signs: Safety-Evaluable Patients
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
BRA-1/236 32/M/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 486 37.04/L 36.11 120.31/H 146.04 65.75 22.69/H
WEEK 2 DAY 15 678 80.66 35.64/L 106.20 146.80 82.04 16.89
WEEK 3 DAY 22 762 86.71 36.16 104.63 76.01/L 70.13 19.70
WEEK 4 DAY 29 773 48.43 35.38/L 111.13 134.79 80.78 17.98
WEEK 5 DAY 36 901 24.05/L 35.90/L 108.01 137.95 68.35 8.48/L
BRA-1/65 25/F/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 546 60.68 34.67/L 113.72 132.45 76.37 16.70
WEEK 2 DAY 15 604 55.85 38.63/H 127.03/H 133.52 93.95 15.08
WEEK 3 DAY 22 723 47.66 37.02 116.06 91.36/L 62.00 3.89/L
WEEK 4 DAY 29 791 116.89/H 37.90/H 113.53 170.65 96.86 6.73/L
WEEK 5 DAY 36 800 56.73 36.81 141.54/H 165.15 75.85 23.02/H
BRA-1/93 34/F/ASIAN WEEK 1 DAY 8 402 47.51 35.50/L 94.27 98.82/L 72.44 14.97
WEEK 2 DAY 15 460 67.64 37.96/H 109.98 104.21/L 104.70/H 14.90
WEEK 3 DAY 22 464 53.06 36.33 90.17 139.66 111.13/H 22.86/H
WEEK 4 DAY 29 496 61.68 33.52/L 112.76 128.82 72.89 20.77/H
WEEK 5 DAY 36 538 53.98 35.71/L 80.20 137.16 96.63 18.10
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
l_vs_slide is generated correctly from the spec.yml
Code
outputs
Output
$l_vs_slide_PP128
Listing of Vital Signs: Safety-Evaluable Patients
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
A: Drug X CHN-3/128 32/M/ASIAN WEEK 1 DAY 8 408 85.96 37.06 77.15/L 160.71 77.01 12.71
WEEK 2 DAY 15 662 104.28/H 36.99 101.50 136.92 51.40/L 13.86
WEEK 3 DAY 22 776 74.19 37.90/H 121.95/H 135.94 74.71 17.84
WEEK 4 DAY 29 923 80.48 36.51 81.22 115.51/L 83.30 15.45
WEEK 5 DAY 36 1015 61.36 38.22/H 76.83/L 164.55 90.36 10.36/L
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
$l_vs_slide_PP262
Listing of Vital Signs: Safety-Evaluable Patients
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
C: Combination CHN-15/262 35/M/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 428 96.54 38.18/H 123.51/H 132.81 79.73 15.30
WEEK 2 DAY 15 471 65.91 34.89/L 109.00 130.82 65.32 11.56/L
WEEK 3 DAY 22 483 93.99 35.14/L 82.01 161.65 61.17 22.53/H
WEEK 4 DAY 29 661 68.79 37.00 127.87/H 155.19 56.88/L 19.64
WEEK 5 DAY 36 1025 73.16 38.41/H 95.87 113.91/L 84.02 18.41
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
$l_vs_slide_PP378
Listing of Vital Signs: Safety-Evaluable Patients
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
C: Combination RUS-3/378 30/F/ASIAN WEEK 1 DAY 8 428 95.11 37.57/H 90.52 113.37/L 83.55 17.54
WEEK 2 DAY 15 501 71.73 38.00/H 96.79 145.53 111.55/H 21.99/H
WEEK 3 DAY 22 701 59.10 36.67 77.14/L 149.26 68.95 17.32
WEEK 4 DAY 29 745 57.88 37.67/H 132.52/H 142.93 86.05 6.36/L
WEEK 5 DAY 36 885 43.44 36.40 97.38 183.98/H 82.18 19.05
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
$l_vs_slide_PP220
Listing of Vital Signs: Safety-Evaluable Patients
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Pressure, Respiratory Rate
Result Temperature Result Result Sitting Pulse Rate Result Result
Study (Kg); (C); (Pa); (Pa); (beats/min); (breaths/min);
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Range:(36.1-37.2) Range:(80-120) Range:(120-180) Range:(60-100) Range:(12-20)
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
B: Placebo CHN-11/220 26/F/ASIAN WEEK 1 DAY 8 284 93.75 33.03/L 132.89/H 165.75 78.09 18.00
WEEK 2 DAY 15 403 64.44 35.93/L 116.93 101.12/L 92.92 18.57
WEEK 3 DAY 22 634 86.18 36.07/L 115.34 134.15 66.07 16.20
WEEK 4 DAY 29 685 70.70 37.16 108.18 145.76 92.05 13.04
WEEK 5 DAY 36 1027 67.53 36.85 137.64/H 187.10/H 74.17 18.61
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.
Try the autoslider.core package in your browser
Any scripts or data that you put into this service are public.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.